// App-Quantinova.ai

378 : Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.

Researchers

Presenter

  • Talia Golan

Principal Investigators

  • Michele Reni

  • Eric Van Cutsem

  • Teresa Macarulla

  • Michael J. Hall

  • Joon Oh Park

  • Daniel Hochhauser

  • Dirk Arnold

  • Do-Youn Oh

  • Anke C. Reinacher-Schick

  • Giampaolo Tortora

  • Hana Algl

  • Eileen Mary O'Reilly

  • David McGuinness

  • Karen Cui

  • Katia Schlienger

  • Gershon Y. Locker

  • Hedy L. Kindler

Medical Centers

  • The Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel

  • Hopital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France

  • San Raffaele Scientific Institute, Milan, Italy

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Fox Chase Cancer Center, Philadelphia, PA

  • Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • Asklepios Tumorzentrum Hamburg, Hamburg, Germany

  • Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)

  • St. Josef-Hospital/Ruhr-University Bochum, Bochum, Germany

  • Klinikum rechts der Isar, Comprehensive Cancer Center Munich TUM, Technische Universität, Munich, Germany

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • AstraZeneca, Gaithersburg, MD

  • Merck & Co., Inc., Kenilworth, NJ

  • The University of Chicago Medical Center, Chicago, IL

Locations

  • Israel

  • France

  • Italy

  • Belgium

  • Spain

  • United States

  • Republic of South Korea

  • United Kingdom

  • Germany

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • Tumor doubling time

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

Phase

  • III

Study Id's

  • NCT02184195

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved